ArticleSchizophrenia bulletin open2025
Efficacy and Safety of Cariprazine, Asenapine, Xanomeline-Trospium, and Lumateperone for Acute Exacerbations of Schizophrenia in Adults: A Network Meta-Analysis.
Article in Schizophrenia bulletin open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and network meta-analysis of the efficacy, safety and tolerability of xanomeline plus trospium chloride compared with eight oral antipsychotics for the acute treatment of schizophrenia.Journal of comparative effectiveness research · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This network meta-analysis evaluated the efficacy and safety of cariprazine, asenapine, xanomeline-trospium chloride, and lumateperone in treating acute exacerbations of schizophrenia in adults, compared with placebo. Methods: A systematic search of PubMed, Scopus, Cochrane Central, and ClinicalTrials.gov identified 12 randomized controlled trials (RCTs; Results: Asenapine (MD = -9.83; 95% CI, -13.49 to -6.18), xanomeline-trospium (MD = -9.80; 95% CI, -13.00 to -6.60), and cariprazine (MD = -8.41; 95% CI, -11.33 to -5.50) showed statistically significant PANSS score reductions. Lumateperone, however, did not reach statistical significance (MD = -2.79; 95% CI, -6.60 to 1.01). Safety profiles varied: cariprazine had the lowest risk of serious AEs (RR = 0.52), while xanomeline-trospium was associated with gastrointestinal AEs (RR = 3.86), and asenapine with weight gain (RR = 3.12). Conclusions: This network meta-analysis found that among asenapine, xanomeline-trospium, lumateperone and cariprazine, asenapine, xanomeline-trospium, and cariprazine were effective in reducing PANSS total score compared with placebo, whereas lumateperone did not show statistically significant reduction compared with placebo. These findings offer important insights into efficacy and safety of these 4 medications in the treatment of acute exacerbation of schizophrenia. However, further head-to-head comparisons with standard treatments are needed to guide a more evidence-based selection. Future trials with longer durations and more diverse populations are warranted to confirm and extend these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.